Feasibility of HPV Testing and Treatment for Cervical Cancer Precursors
Feasibility and Acceptability of Implementing Integrated HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions in Burkina Faso, Côte d'Ivoire, Guatemala, and the Philippines
Jhpiego · NCT05133661
This study is testing if women in Burkina Faso, Côte d'Ivoire, Guatemala, and the Philippines can easily use self-testing for HPV and get treatment for precancerous cervical changes to help prevent cervical cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 17602 (estimated) |
| Ages | 25 Years to 49 Years |
| Sex | All |
| Sponsor | Jhpiego (other) |
| Locations | 4 sites (Ouagadougou and 3 other locations) |
| Trial ID | NCT05133661 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the feasibility and acceptability of integrating HPV screening and treatment for precancerous cervical lesions into existing health systems in Burkina Faso, Côte d'Ivoire, Guatemala, and the Philippines. It will assess the implementation of self-collection HPV testing and ablative treatments among women aged 30-49 and women living with HIV aged 25-49. The study will also analyze the costs associated with these services and the factors influencing their successful implementation. By leveraging local health systems, the findings will inform strategies for cervical cancer prevention and treatment in low-and-middle income countries.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 30-49 years and women living with HIV aged 25-49 years who are seeking cervical cancer services in the participating countries.
Not a fit: Patients who are pregnant or unwilling to participate in the study may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this study could enhance cervical cancer prevention and treatment services, potentially reducing the incidence of cervical cancer in underserved populations.
How similar studies have performed: Other studies have shown success in implementing similar HPV screening and treatment approaches, particularly in low-resource settings, indicating a promising avenue for cervical cancer prevention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women: Participants will be women residing in the study area, seeking services at SUCCESS project-supported health facilities, and meet the eligibility criteria to be enrolled in one of the components of the study (i.e, prospective component, client exit interviews and/or in-depth interviews). * Service providers: Health care personnel working in the project facilities at the time of the study providing services related to cervical cancer screening and treatment. Facility in-charges and laboratory personnel are included in this category. * Key informants: Health program managers, and community mobilizers at either local or national level in Burkina Faso, Cote d'Ivoire, Guatemala, and Philippines. * Men: Male members of the community (married or cohabiting with female partners) to gather their perspectives on the implementation of the cervical cancer prevention and treatment activities. Exclusion Criteria: * Pregnant women * Individuals unwilling to participate or unable to provide informed consent
Where this trial is running
Ouagadougou and 3 other locations
- CMA de Do — Ouagadougou, Burkina Faso (RECRUITING)
- FSU Koko — Bouaké, Côte D'Ivoire (COMPLETED)
- Quetzaltenango — Quetzaltenango, Guatemala (COMPLETED)
- Metro-Manila — Quezon City, Philippines (RECRUITING)
Study contacts
- Study coordinator: MARK M KABUE, Dr.PH
- Email: Mark.Kabue@jhpiego.org
- Phone: (1)4433266518
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cervical Cancer, HPV Screening, Precancerous lesions, Thermal ablation